In conclusion, the present study findings add further evidence that CHIT1 and YKL-40 are upregulated in patients with IPF, and suggest that longitudinally stable serum CHIT1 activity and YKL-40 concentrations may potentially be associated with the antifibrotic treatment response. The gene discussed is CHIT1; the disease is idiopathic pulmonary fibrosis.